Mallia P, Contoli M, Caramori G, Pandit A, Johnston S L, Papi A
Department of Respiratory Medicine, National Heart and Lung Institute and Wright Fleming Institute of Infection & Immunity, Imperial College London, UK.
Curr Pharm Des. 2007;13(1):73-97. doi: 10.2174/138161207779313777.
Asthma and chronic obstructive pulmonary disease (COPD) are the 2 most prevalent chronic airway diseases. Much of the morbidity, mortality and health care costs of the diseases are associated with acute exacerbations, which are episodes of increased symptoms and airflow obstruction. Over the last decade evidence has emerged implicating virus respiratory tract infections as a major cause of exacerbations of both asthma and COPD. Current therapies are not very effective in the prevention or treatment of virus-induced exacerbations and exacerbations are therefore a major unmet medical need. The development of new and novel treatments requires a better understanding of the molecular and cellular mechanisms linking virus infection with exacerbations of asthma and COPD. This article provides an overview of current knowledge regarding the mechanisms of virus-induced exacerbations in both asthma and COPD. It will also review existing treatments and future treatments that are in advanced stages of development.
哮喘和慢性阻塞性肺疾病(COPD)是两种最常见的慢性气道疾病。这些疾病的大部分发病率、死亡率和医疗费用都与急性加重有关,急性加重是指症状加重和气流受限的发作。在过去十年中,有证据表明病毒呼吸道感染是哮喘和COPD加重的主要原因。目前的治疗方法在预防或治疗病毒诱发的加重方面效果不佳,因此加重是一个主要未满足的医疗需求。开发新的治疗方法需要更好地了解将病毒感染与哮喘和COPD加重联系起来的分子和细胞机制。本文概述了目前关于哮喘和COPD中病毒诱发加重机制的知识。它还将回顾现有治疗方法以及处于研发后期的未来治疗方法。